Literature DB >> 17709495

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Yong Tang1, Jianlong Lou, R Katherine Alpaugh, Matthew K Robinson, James D Marks, Louis M Weiner.   

Abstract

Unconjugated mAbs have emerged as useful cancer therapeutics. Ab-dependent cellular cytotoxicity (ADCC) is believed to be a major antitumor mechanism of some anticancer Abs. However, the factors that regulate the magnitude of ADCC are incompletely understood. In this study, we described the relationship between Ab affinity and ADCC. A series of human IgG1 isotype Abs was created from the anti-HER2/neu (also named c-erbB2) C6.5 single-chain Fv (scFv) and its affinity mutants. The scFv affinities range from 10(-7) to 10(-11) M, and the IgG Abs retain the affinities of the scFv from which they were derived. The apparent affinity of the Abs ranged from nearly 10(-10) M (the lowest affinity variant) to almost 10(-11) M (the other variants). The IgG molecules were tested for their ability to elicit ADCC in vitro against three tumor cell lines with differing levels of HER2/neu expression using unactivated human PBMC from healthy donors as the effector cells. The results demonstrated that both the apparent affinity and intrinsic affinity of the Abs studied regulate ADCC. High-affinity tumor Ag binding by the IgGs led to the most efficient and powerful ADCC. Tumor cells expressing high levels of HER2/neu are more susceptible to the ADCC triggered by Abs than the cells expressing lower amounts of HER2/neu. These findings justify the examination of high affinity Abs for ADCC promotion. Because high affinity may impair in vivo tumor targeting, a careful examination of Ab structure to function relationships is required to develop optimized therapeutic unconjugated Abs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709495     DOI: 10.4049/jimmunol.179.5.2815

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Authors:  Tracy R Daniels; Richard K Leuchter; Rafaela Quintero; Gustavo Helguera; José A Rodríguez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-11-30       Impact factor: 6.968

2.  Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Authors:  Smitha Reddy; Calvin C Shaller; Mohan Doss; Irina Shchaveleva; James D Marks; Jian Q Yu; Matthew K Robinson
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

3.  Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Authors:  Janine Stubbs; Sope Olugbile; Balam Saidou; Jacques Simpore; Giampietro Corradin; Antonio Lanzavecchia
Journal:  Infect Immun       Date:  2010-12-28       Impact factor: 3.441

4.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

5.  Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.

Authors:  D C Stylianou; A Auf der Maur; D P Kodack; R T Henke; S Hohn; J A Toretsky; A T Riegel; A Wellstein
Journal:  Oncogene       Date:  2009-07-27       Impact factor: 9.867

Review 6.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

7.  Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.

Authors:  Fan Zhang; Jie Zhang; Moyan Liu; Lichao Zhao; RuiXia LingHu; Fan Feng; Xudong Gao; Shunchang Jiao; Lei Zhao; Yi Hu; Junlan Yang
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

8.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

9.  A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity.

Authors:  Diana Rasoulouniriana; Nadine Santana-Magal; Amit Gutwillig; Leen Farhat-Younis; Yariv Wine; Corey Saperia; Lior Tal; Haim Gutman; Alexander Tsivian; Ronen Brenner; Eiman Abu Bandora; Nathan E Reticker-Flynn; Peleg Rider; Yaron Carmi
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 10.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.